SCHEMBL1965209

SCHEMBL1965209

Cc1nc2ccncc2c(=O)n1-c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALOX12 P18054 1/20 0.70
HRH3 Q9Y5N1 1/20 0.56
MAPK1 P28482 2/20 0.55
HSD17B10 Q99714 1/20 0.55
POLB P06746 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
GRM1 Q13255 3/20 0.50
ALDH1A1 P00352 2/20 0.50
GRM5 P41594 1/20 0.49
MDM2 Q00987 1/20 0.49
MEN1 O00255 1/20 0.49
HSP90AA1 P07900 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
LMNA P02545 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30454788 0.82 ALOX12 (1.00) ALOX12MAPK1HSD17B10POLBSMN1; SMN2
SCHEMBL30122631 0.82 MAPK1 (0.75) ALOX12MAPK1HSD17B10POLBSMN1; SMN2
SCHEMBL1682746 0.82 MAPK1 (0.75) ALOX12MAPK1HSD17B10POLBSMN1; SMN2
SCHEMBL9611693 0.80 MAPK1 (0.67) ALOX12MAPK1HSD17B10SMN1; SMN2ALDH1A1
SCHEMBL30293362 0.78 ALOX12 (0.46) ALOX12HRH3MAPK1ALDH1A1MEN1
SCHEMBL1963855 0.77 HSD17B10 (0.52) ALOX12MAPK1HSD17B10POLBSMN1; SMN2
SCHEMBL22021644 0.76 ALOX12 (0.44) ALOX12HRH3MAPK1SMN1; SMN2ALDH1A1
SCHEMBL540767 0.76 MAPK1 (0.67) ALOX12MAPK1HSD17B10SMN1; SMN2ALDH1A1
SCHEMBL2631381 0.75 MAPK1 (0.74) ALOX12MAPK1HSD17B10POLBSMN1; SMN2
SCHEMBL15302024 0.75 NPC1 (0.70) HRH3HSD17B10POLBSMN1; SMN2GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC (US) 2017-08-10 US disclosed
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC (US) 2017-08-10 US disclosed
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC (US) 2017-08-10 US disclosed
US-9486455-B2 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
US-9486455-B2 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
US-9486455-B2 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2014-06-05 US disclosed
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2014-06-05 US disclosed
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2014-06-05 US disclosed
US-8552009-B2 Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. 2013-10-08 US disclosed
US-20100152209-A1 Compounds for Modulating TRPV3 Function HYDRA BIOSCIENCES INC. (US) 2010-06-17 US disclosed
US-20100152209-A1 Compounds for Modulating TRPV3 Function HYDRA BIOSCIENCES INC. (US) 2010-06-17 US disclosed
US-20090018147-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES INC. (US) 2009-01-15 US disclosed
US-20090018147-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES INC. (US) 2009-01-15 US disclosed
US-20090018147-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES INC. (US) 2009-01-15 US disclosed
WO-2008140750-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC. (US) 2008-11-20 WO disclosed
US-20070179164-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2007-08-02 US disclosed
US-20070179164-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2007-08-02 US disclosed
US-20070179164-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2007-08-02 US disclosed
WO-2007056124-A2 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION TRPV3, TRPV1, TRPV4 ALOX12 736/4885HRH3 1036/4885MAPK1 2094/4885
US-20090018147-A1 Compounds for modulating TRPV3 function TRPV3, TRPV1, TRPV4 ALOX12 736/4885HRH3 1036/4885MAPK1 2094/4885
US-20100152209-A1 Compounds for Modulating TRPV3 Function TRPV3, TRPV1, TRPV4 ALOX12 736/4885HRH3 1036/4885MAPK1 2094/4885
US-20070179164-A1 Compounds for modulating TRPV3 function TRPV3, TRPV1, TRPV4 ALOX12 736/4885HRH3 1036/4885MAPK1 2094/4885
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION TRPV3, TRPV1, TRPV4 ALOX12 736/4885HRH3 1036/4885MAPK1 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.